NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NKTR

Nektar Therapeutics

Jul 11 • 04:00PM ET

25.01

Dollar change -0.09
Percentage change -0.36	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF PINK SCHA FESM PRFZ VTWO SCHB QQQS VTWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.53	Insider Own	26.52%	Shs Outstand	17.30M	Perf Week	1.01%
Market Cap	432.69M	Forward P/E	-	EPS next Y	-12.29	Insider Trans	-1.90%	Shs Float	12.71M	Perf Month	120.35%
Enterprise Value	400.72M	PEG	-	EPS next Q	-3.03	Inst Own	-	Short Float	9.57%	Perf Quarter	226.54%
Income	-133.04M	P/S	4.96	EPS this Y	-33.49%	Inst Trans	5.15%	Short Ratio	0.72	Perf Half Y	40.11%
Sales	87.25M	P/B	22.59	EPS next Y	-5.83%	ROA	-40.79%	Short Interest	1.22M	Perf YTD	79.28%
Book/sh	1.11	P/C	1.98	EPS next 5Y	-18.15%	ROE	-189.46%	52W High	37.38 -33.09%	Perf Year	35.56%
Cash/sh	12.64	P/FCF	-	EPS past 3/5Y	41.29% 25.49%	ROIC	-74.51%	52W Low	6.48 285.96%	Perf 3Y	-57.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.15% -3.00%	Gross Margin	74.12%	Volatility	9.76% 17.43%	Perf 5Y	-93.05%
Dividend TTM	-	EV/Sales	4.59	EPS Y/Y TTM	31.00%	Oper. Margin	-160.27%	ATR (14)	2.98	Perf 10Y	-85.98%
Dividend Ex-Date	-	Quick Ratio	3.24	Sales Y/Y TTM	-3.24%	Profit Margin	-152.49%	RSI (14)	65.90	Recom	1.75
Dividend Gr. 3/5Y	- -	Current Ratio	3.24	EPS Q/Q	-27.65%	SMA20	27.80%	Beta	0.98	Target Price	94.83
Payout	-	Debt/Eq	13.59	Sales Q/Q	-51.66%	SMA50	77.96%	Rel Volume	0.71	Prev Close	25.10
Employees	61	LT Debt/Eq	12.00	Earnings	May 08 AMC	SMA200	71.86%	Avg Volume	1.69M	Price	25.01
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	-40.39% -31.87%	Trades		Volume	1,206,950	Change	-0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5

Show Previous Ratings

Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Loading…
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)
Jun-25-25 06:45PM	Why Nektar Therapeutics Stock Was Red-Hot Today (Motley Fool) +19.10%
12:20PM	Wainwright sets over $100 target for Nektar on paradigm-shifting data (TipRanks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 04:23PM	Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment (Investor's Business Daily) +156.29%
10:54AM	Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results (Investopedia)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:07AM	Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam (Investor's Business Daily)
07:30AM	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
04:30PM	Loading…
Jun-23-25 04:30PM	Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 (PR Newswire) +12.10%
May-13-25 05:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (PR Newswire)
May-09-25 02:29PM	Q1 2025 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:46AM	Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... (GuruFocus.com)
May-08-25 06:25PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:20PM	Nektar Therapeutics Q1 2025 Earnings Preview (Seeking Alpha) -5.67%
May-01-25 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-11-25 02:29PM	Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 (GuruFocus.com) +23.76%
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Mar-22-25 06:57PM	Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-20-25 06:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
07:33AM	Loading…
Mar-14-25 07:33AM	Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) (Zacks) +9.98%
Mar-13-25 12:06PM	Q4 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Mar-12-25 08:30PM	Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:00PM	Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates (Zacks)
06:12PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-05-25 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-27-25 10:59AM	Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata (Clinical Trials Arena)
Feb-26-25 07:00AM	Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata (PR Newswire) -10.38%
Feb-24-25 07:00AM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th (PR Newswire) -9.35%
07:00AM	Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus (PR Newswire)
Feb-10-25 07:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Feb-07-25 09:35AM	Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround (Zacks)
Jan-31-25 09:55AM	Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-10-25 07:00AM	Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire) -9.65%
Jan-07-25 09:24AM	Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-07-24 12:00PM	Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting (PR Newswire)
Nov-18-24 03:30PM	Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence (PR Newswire)
Nov-08-24 02:30AM	Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook (GuruFocus.com)
Nov-07-24 05:40PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:36PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire)
10:15AM	Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Nov-06-24 06:00PM	Nektar Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-05-24 10:34AM	Nektar Therapeutics to sell Alabama facility to Ampersand (Pharmaceutical Technology) +5.26%
Nov-04-24 01:44PM	Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential (Benzinga) +8.13%
08:30AM	Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama (PR Newswire)
Oct-31-24 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-29-24 09:00AM	Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases (PR Newswire) -6.62%
Oct-17-24 12:07PM	Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (PR Newswire) +5.07%
Sep-25-24 03:30AM	Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 (PR Newswire)
Sep-03-24 09:00AM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire)
Aug-13-24 12:00PM	What Makes Nektar (NKTR) a New Buy Stock (Zacks)
Aug-09-24 10:58AM	Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top (Zacks) -8.26%
Aug-08-24 05:55PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:49PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.22% -5.51%
Jun-12-24 09:30AM	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 (PR Newswire)
May-30-24 06:00PM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire) -8.70%
May-10-24 04:41PM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.00%
03:14PM	Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview (GuruFocus.com)
11:33AM	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates (Zacks)
10:35AM	Q1 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:39PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
May-02-24 06:00PM	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.99%
Apr-03-24 11:30AM	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks) +9.47%
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 02:00PM	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-06-24 12:33PM	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata (Zacks)
Mar-05-24 10:07AM	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat (Zacks)
09:13AM	Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata (PR Newswire)
07:19AM	Q4 2023 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 05:30PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.38%
04:51PM	Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results (GuruFocus.com)
04:42PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
08:30AM	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX (PR Newswire)
Feb-27-24 06:00PM	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference (PR Newswire) +11.94%
Feb-26-24 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-20-24 10:00AM	Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know (Zacks) -6.78%
Jan-03-24 06:00PM	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) -6.36%
Dec-11-23 06:00PM	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire) -5.94%
Dec-07-23 11:31AM	Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 08:39AM	Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.00%
Nov-08-23 11:47AM	Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss (Zacks) -8.76%
Nov-07-23 05:28PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 19 '25	Sale	1.01	10,300	10,403	316,604	Feb 21 06:07 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 19 '25	Sale	1.01	11,040	11,150	324,292	Feb 21 06:06 PM
ROBIN HOWARD W	President & CEO	Feb 19 '25	Sale	1.01	23,774	24,012	1,086,901	Feb 21 06:04 PM
Wilson Mark Andrew	Officer	Feb 19 '25	Proposed Sale	1.01	11,040	11,137		Feb 19 03:27 PM
ROBIN HOWARD W	Officer	Feb 19 '25	Proposed Sale	1.01	23,774	23,983		Feb 19 03:21 PM
Zalevsky Jonathan	Officer	Feb 19 '25	Proposed Sale	1.01	10,300	10,391		Feb 19 03:18 PM
Wilson Mark Andrew	Chief Legal Officer	Dec 23 '24	Sale	0.90	33,402	30,062	351,892	Dec 26 07:04 PM
Wilson Mark Andrew	Chief Legal Officer	Dec 24 '24	Sale	0.89	16,560	14,738	335,332	Dec 26 07:04 PM
Wilson Mark Andrew	Officer	Dec 24 '24	Proposed Sale	0.89	16,560	14,801		Dec 26 09:35 AM
Wilson Mark Andrew	Officer	Dec 23 '24	Proposed Sale	0.90	33,402	29,898		Dec 23 03:21 PM
Zalevsky Jonathan	Chief R&D Officer	Dec 19 '24	Sale	0.94	51,115	48,048	326,904	Dec 20 08:33 PM
ROBIN HOWARD W	President & CEO	Dec 18 '24	Sale	0.99	85,035	84,185	1,110,675	Dec 19 09:08 PM
ROBIN HOWARD W	President & CEO	Dec 17 '24	Sale	1.01	46,995	47,465	1,195,710	Dec 19 09:08 PM
Zalevsky Jonathan	Officer	Dec 19 '24	Proposed Sale	0.94	51,115	48,063		Dec 19 03:12 PM
ROBIN HOWARD W	Officer	Dec 18 '24	Proposed Sale	0.99	85,035	84,244		Dec 18 04:17 PM
ROBIN HOWARD W	Officer	Dec 17 '24	Proposed Sale	1.01	46,995	47,338		Dec 17 03:29 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 19 '24	Sale	1.01	7,785	7,863	243,019	Nov 20 08:37 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 19 '24	Sale	1.01	6,407	6,471	218,856	Nov 20 08:36 PM
ROBIN HOWARD W	President & CEO	Nov 19 '24	Sale	1.01	16,278	16,441	832,080	Nov 20 08:36 PM
Zalevsky Jonathan	Officer	Nov 19 '24	Proposed Sale	1.01	7,785	7,878		Nov 19 04:10 PM
Wilson Mark Andrew	Officer	Nov 19 '24	Proposed Sale	1.01	6,407	6,483		Nov 19 03:28 PM
ROBIN HOWARD W	Officer	Nov 19 '24	Proposed Sale	1.01	16,278	16,472		Nov 19 03:17 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '24	Sale	1.28	6,866	8,788	250,804	Aug 20 09:15 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '24	Sale	1.28	5,651	7,233	225,263	Aug 20 09:15 PM
ROBIN HOWARD W	President & CEO	Aug 19 '24	Sale	1.28	14,881	19,048	848,358	Aug 20 09:14 PM
Wilson Mark Andrew	Officer	Aug 19 '24	Proposed Sale	1.28	5,651	7,211		Aug 19 04:13 PM
ROBIN HOWARD W	Officer	Aug 19 '24	Proposed Sale	1.28	14,881	18,990		Aug 19 04:03 PM
Zalevsky Jonathan	Officer	Aug 19 '24	Proposed Sale	1.28	6,866	8,762		Aug 19 03:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience